Table 2 Association between MMP expression profiles and ENE presence in metastatic LNs
| Â | LN(+)/ENE(-) | LN(+)/ENE(+) | p-value |
|---|---|---|---|
Intranodal MMP14 expression | Â | ||
CAFs |  |  | < 0.01 |
Negative | 11 (65%) | 6 (35%) | Â |
Positive | 6 (22%) | 21 (78%) | Â |
Tumour nest | Â | 0.03 | |
Low | 12 (55%) | 10 (45%) | Â |
High | 5 (23%) | 17 (77%) | Â |
MMP14 co-scoring system | Â | 0.01 | |
Low-risk | 14 (54%) | 12 (46%) | Â |
High-risk | 3 (17%) | 15 (83%) | Â |
Intranodal MMP2 expression | Â | ||
CAFs | Â | Â | 0.98 |
Negative | 7 (39%) | 11 (61%) | Â |
Positive | 10 (38%) | 16 (62%) | Â |
Tumour nest | Â | 0.51 | |
Low | 9 (35%) | 17 (65%) | Â |
High | 8 (44%) | 10 (56%) | Â |
Intranodal MMP3 expression | Â | ||
CAFs | Â | Â | 0.8 |
Negative | 12 (38%) | 20 (63%) | Â |
Positive | 5 (42%) | 7 (58%) | Â |
Tumour nest | Â | 0.58 | |
Low | 13 (39%) | 20 (61%) | Â |
High | 4 (36%) | 7 (64%) | Â |
Intranodal MMP9 expression | Â | ||
CAFs | Â | Â | 0.49 |
Negative | 10 (43%) | 13 (57%) | Â |
Positive | 7 (33%) | 14 (67%) | Â |
Tumour nest | Â | 0.5 | |
Low | 15 (38%) | 25 (63%) | Â |
High | 2 (50%) | 2 (50%) | Â |